Europe * , Middle East and Africa (EMEA) We will drive sustained growth by expanding the ur ology  franchise and quickly establishing a business platform in  the oncology field. * Includes NIS countries Astellas Pharma Inc.  _ Annual Report 2014 48 Fiscal 2013 Overview *Sales and year-on-year changes are based on J-GAAP. Net sales in EMEA in fiscal 2013 grew 8.5% to  € 1,990 million. When  converted to yen, net sales rose 36.1% to ¥267.4 billion. By product, sales of Vesicare continued to show steady growth, up  strongly by 13.0% on a euro basis. The new products BETMIGA and  XTANDI contributed to increased sales. Furthermore, sales of MYCAMINE  grew steadily. Sales of Omnic, which goes by the brand name Harnal in  Japan, through our own distribution channel were mostly unchanged from  the previous fiscal year. Meanwhile, although sales of Advagraf continued  growing in EMEA, sales of Prograf (including the Advagraf formulation)  through our own distribution channel recorded a 1.3% decline on a euro  basis due to the impact of generic products. In terms of new products, we launched VESOMNI, a Vesicare/Omnic  combination drug, in September 2013. Fiscal 2014 Outlook *Sales and year-on-year changes are based on IFRS. In fiscal 2014, we project an 11.0% increase in net sales in EMEA to  € 2,183 million on a euro basis. This equates to ¥305.6 billion in yen  terms, representing a 15.6% increase. Our forecast is based on ongoing  growth in sales of XTANDI, as well as OAB treatments Vesicare and  BETMIGA. Although sales of Prograf are forecast to decline on a euro  basis, we expect the foreign exchange impact to result in higher sales for  this product on a yen basis. Net Sales ( €  million) 2,500 2,000 1,500 1,000 500 0 2012.3 2013.3 2014.3 2015.3 J-GAAP IFRS (Forecast) Japan 46.5% Asia & Oceania 5.1% EMEA 23.2% Sales by Geographical Area 2014.3 Americas 25.2% Note: Yen base *Calculated according to the location of sellers *IFRS